Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02478489 · ClinicalTrials.gov registry record · Phase 4
Alcohol Disorder hOsPital Treatment Trial
A Phase 4 study, sponsored by Boston University.
- Completed
- Registry status
- Phase 4
- Development phase
- 248
- Enrollment target
NCT02478489 is a Phase 4 study that has completed, run by Boston University. The registered enrollment target is 248 participants.
The verdict
NCT02478489, a Phase 4 study, has completed, sponsored by Boston University.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 248 participants
- Enrollment target
Study Summary
The specific aims of this pragmatic randomized controlled trial are to compare initiating injectable extended release naltrexone (XR-NTX) or oral naltrexone (PO-NTX) at the time of discharge from a medical hospitalization for patients with alcohol use disorder (AUD) on: 1) alcohol consumption and consequences, and 2) acute healthcare utilization (including hospital readmission and emergency visits) and cost-effectiveness. In exploratory analyses, the investigators will assess moderators of medication effects including demographic, behavioral, and genetic factors.
Interventions
- DRUG Oral naltrexone (PO-NTX)
- DRUG Extended-release injectable naltrexone (XR-NTX)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 248 participants |
| Start Date | 2016-06 |
| Est. Completion | 2020-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02478489
The ClinicalTrials.gov registry entry for NCT02478489 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 248 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Oral naltrexone (PO-NTX) is the first listed.
NCT02478489 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02478489 about?
NCT02478489 is a clinical study titled "Alcohol Disorder hOsPital Treatment Trial". The specific aims of this pragmatic randomized controlled trial are to compare initiating injectable extended release naltrexone (XR-NTX) or oral naltrexone (PO-NTX) at the time of discharge from a medical hospitalization for patients with alcohol use disorder (AUD) on: 1) alcohol consumption and co...
What is the current status of trial NCT02478489?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 248 participants. The study started on 2016-06. Estimated completion is 2020-10.
What interventions are being tested in trial NCT02478489?
The interventions under investigation include: Oral naltrexone (PO-NTX) (DRUG), Extended-release injectable naltrexone (XR-NTX) (DRUG).
Who is sponsoring clinical trial NCT02478489?
This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.